May 4 (Reuters) - Moderna Inc on Wednesday maintained the full-year sales forecast for its COVID-19 vaccine at $21 billion, as cases fall and demand slackens after countries rushed to secure shots last year. (Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
111.5 USD | +3.25% | +6.71% | +12.09% |
03:02pm | Moderna Signs Nonexclusive License Deal in Japan for COVID-19-related Intellectual Property | MT |
04-24 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.09% | 41.34B | |
+2.42% | 42.75B | |
+47.70% | 41.61B | |
-8.83% | 26.59B | |
+6.84% | 25.49B | |
-22.84% | 18.12B | |
+30.41% | 12.24B | |
-2.08% | 11.76B | |
+9.14% | 11B | |
-15.58% | 10.07B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna keeps full-year COVID vaccine sales view unchanged